WOKCZJHFODBSMM-RGEXLXHISA-N
C30H26ClF3N4O5 — CID 59406634
Data last refreshed: (MolForge compound catalog, from PubChem)
About WOKCZJHFODBSMM-RGEXLXHISA-N
WOKCZJHFODBSMM-RGEXLXHISA-N (PubChem CID 59406634) has the molecular formula C30H26ClF3N4O5 and a molecular weight of 615.01 g/mol. Its IUPAC name is ethyl 3-[2-[(Z)-[5-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-2-oxo-1H-indol-3-ylidene]methyl]-4-oxo-1,5,6,7-tetrahydroindol-3-yl]propanoate.
Molecular Properties
| Compound Name | WOKCZJHFODBSMM-RGEXLXHISA-N |
|---|---|
| PubChem CID | 59406634 |
| Molecular Formula | C30H26ClF3N4O5 |
| Molecular Weight | 615.01 g/mol |
| Exact Mass | 614.15 |
| IUPAC Name | ethyl 3-[2-[(Z)-[5-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-2-oxo-1H-indol-3-ylidene]methyl]-4-oxo-1,5,6,7-tetrahydroindol-3-yl]propanoate |
| SMILES | CCOC(=O)CCc1c(/C=C2\C(=O)Nc3ccc(NC(=O)Nc4ccc(Cl)c(C(F)(F)F)c4)cc32)[nH]c2c1C(=O)CCC2 |
| InChI | InChI=1S/C30H26ClF3N4O5/c1-2-43-26(40)11-8-17-24(37-23-4-3-5-25(39)27(17)23)14-19-18-12-15(7-10-22(18)38-28(19)41)35-29(42)36-16-6-9-21(31)20(13-16)30(32,33)34/h6-7,9-10,12-14,37H,2-5,8,11H2,1H3,(H,38,41)(H2,35,36,42)/b19-14- |
| InChIKey | WOKCZJHFODBSMM-RGEXLXHISA-N |
| XLogP | 6.84 |
| TPSA | 129.39 Ų |
| H-Bond Donors | 4 |
| H-Bond Acceptors | 5 |
| Rotatable Bonds | 7 |
| Heavy Atoms | 43 |
| Complexity | — |
Lipinski Rule of Five
2 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 615.01 |
| LogP ≤ 5 | 6.84 |
| H-Bond Donors ≤ 5 | 4 |
| H-Bond Acceptors ≤ 10 | 5 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'Michael_acceptor_1', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 59406634 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.